Meningitis B vaccine: why a million young people in the UK are being offered the shot

In one of the broadest expansions of the UK immunisation programme in recent years, NHS officials have said the Bexsero vaccine against meningitis B will be offered to school leavers and incoming university students. According to the BBC Health report, the first phase will cover around a million young people and will begin in the autumn.

What is meningitis B? It is a serious infection caused by the B serogroup of the Neisseria meningitidis bacterium, in which the meninges — the thin membranes covering the brain and spinal cord — become inflamed. The illness can turn into sepsis within hours and can result in limb loss, deafness, permanent neurological damage and death. Babies in the UK have been offered the vaccine on the routine schedule since 2015.

Why target school leavers and university students? The incidence of meningitis B peaks for a second time in the 16 to 24 age group. Young adults start living in group settings, share intense social environments and form an efficient population for the chain of infection. NHS data show that meningitis B cases rise above the annual average in the first weeks of university enrolment.

Understanding how the vaccine works means looking at bacterial surface proteins. Bexsero uses four different meningococcal B antigens to prime the immune system to recognise the bacterium. After a two-dose series, clinical trials show a protection level of around 75 to 95 per cent against the various B strains, depending on the study.

The NHS has said the programme will be run mainly through school and university health services rather than individual invitation letters. The aim is to enable rapid, group-based vaccination coverage. Scientific advisors stress that sending information packs to families and young people will be critical for a strong uptake rate.

The economic logic goes beyond the cost per dose. A single case of meningitis B can cost the NHS millions of pounds in intensive care, rehabilitation, prosthetic care and long-term disability support. The independent vaccine advisory body, the JCVI, has been studying the cost-effectiveness of broad adolescent vaccination for years; the announcement is the end-point of that long review.

The international context matters. In the United States, the B serogroup vaccine is individually recommended around university enrolment, while the United Kingdom is now moving to a population-based approach. Ireland, the Czech Republic and Lithuania have expanded adolescent meningitis vaccination. In Türkiye the meningitis B vaccine is not currently on the Ministry of Health's routine schedule; it is accessible at private clinics.

Specialists also remind families that symptom awareness saves lives. Classical signs of meningitis B include sudden high fever, severe headache, light sensitivity, neck stiffness, and a non-blanching red-purple rash on the skin. Symptoms can start as flu-like and become life-threatening within hours; BBC Health reports that young people in shared housing are being asked to check on each other.

On possible risks and side effects, the most commonly reported reaction to Bexsero is injection-site pain and mild fever. The serious side effect rate in approval data worldwide, including in Türkiye, is very low. Even so, medical advice should be obtained; anyone on existing immunosuppressive treatment should plan timing with their doctor.

The NHS message in the bigger picture is clear: the programme is voluntary but strongly recommended. JCVI chair Professor Anthony Harnden told the BBC, "This disease is rare but devastating and rapid protection can change a great deal." For young people the message is to check with their GP and university health service for eligibility before term starts.